Search results
Results From The WOW.Com Content Network
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union Army veteran of the American Civil War for whom the company was later named.
May 21, 2024 at 4:14 AM. (Reuters) -Aktis Oncology said on Tuesday it will collaborate with Eli Lilly to develop cancer therapies, making it eligible for milestone payments of up to $1.1 billion ...
Galunisertib (LY2157299) is a small molecular experimental cancer drug previously in development by Eli Lilly. It is a TGF-b inhibitor. [1] Development of galunisertib by Eli Lilly was discontinued in January 2020. [2] Galunisertib was investigated in a phase II trial for treatment of hepatocellular carcinoma. [3]
Website. boehringer-ingelheim .com. C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one.
In December 2023, Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced updated interim clinical data on MCLA-129 from ongoing expansion cohorts in non-small cell lung cancer and in previously treated head and neck squamous cell carcinoma (HNSCC) were presented at the European ...
We recently looked at Lilly's current product lineup and identified several. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 more ways to ...
For premium support please call: 800-290-4726 more ways to reach us
CytRx Corp. is a biopharmaceutical research and development oncology company based in Los Angeles, California . The CytRx oncology pipeline includes clinical trials involving their lead drug aldoxorubicin. Aldoxorubicin (formerly INNO-206) is a modified form of doxorubicin, the popular anthracycline chemotherapeutic agent known as "red death".